Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
about
PREVALENCE OF SMALL INTESTINE BACTERIAL OVERGROWTH IN PATIENTS WITH GASTROINTESTINAL SYMPTOMS.Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea.Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.
P2860
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Update on the Management of Di ...... on Rifaximin and Eluxadoline.
@en
type
label
Update on the Management of Di ...... on Rifaximin and Eluxadoline.
@en
prefLabel
Update on the Management of Di ...... on Rifaximin and Eluxadoline.
@en
P2860
P356
P1433
P1476
Update on the Management of Di ...... on Rifaximin and Eluxadoline.
@en
P2093
Anastasia Rivkin
Sergey Rybalov
P2860
P304
P356
10.1002/PHAR.1712
P407
P577
2016-03-11T00:00:00Z